Ensign Peak Advisors Inc Sells 3,030 Shares of Glaukos Co. (NYSE:GKOS)

Ensign Peak Advisors Inc lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Get Rating) by 16.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,540 shares of the medical instruments supplier’s stock after selling 3,030 shares during the period. Ensign Peak Advisors Inc’s holdings in Glaukos were worth $827,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Quadrant Capital Group LLC boosted its stake in shares of Glaukos by 262.4% in the third quarter. Quadrant Capital Group LLC now owns 1,011 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 732 shares during the period. Captrust Financial Advisors boosted its stake in shares of Glaukos by 17.1% in the second quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 254 shares during the period. AlphaCrest Capital Management LLC bought a new position in shares of Glaukos in the third quarter worth about $205,000. HighTower Advisors LLC bought a new position in shares of Glaukos in the first quarter worth about $208,000. Finally, Everett Harris & Co. CA bought a new position in shares of Glaukos in the third quarter worth about $210,000. Institutional investors own 92.17% of the company’s stock.

Glaukos Trading Down 0.2 %

Shares of GKOS stock opened at $45.25 on Tuesday. Glaukos Co. has a 1 year low of $33.33 and a 1 year high of $64.49. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.13 and a quick ratio of 5.61. The stock’s 50 day simple moving average is $48.50 and its two-hundred day simple moving average is $49.60. The company has a market cap of $2.17 billion, a PE ratio of -21.65 and a beta of 1.24.

Glaukos (NYSE:GKOS – Get Rating) last issued its quarterly earnings data on Wednesday, February 22nd. The medical instruments supplier reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.03. Glaukos had a negative return on equity of 18.51% and a negative net margin of 35.07%. The business had revenue of $71.23 million for the quarter, compared to the consensus estimate of $67.71 million. Research analysts predict that Glaukos Co. will post -2.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on GKOS shares. Needham & Company LLC dropped their price objective on Glaukos from $58.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, February 23rd. Stephens decreased their target price on Glaukos from $69.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 28th. StockNews.com downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Thursday, February 23rd. Wells Fargo & Company decreased their target price on Glaukos from $56.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, December 12th. Finally, Citigroup boosted their target price on Glaukos from $57.00 to $59.00 and gave the stock a “buy” rating in a research report on Thursday, February 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $56.67.

Glaukos Profile

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.